47 results about "Peripheral nervous system" patented technology

The application provides a wireless and battery-free brain nerve stimulator and a preparation method. The brain nerve stimulator can be driven by a mobile phone loudspeaker, and a resonator designed can effectively amplify a piezoelectric signal. The brain nerve stimulator comprises two parts: a base provided with implantable nerve stimulation electrodes and a resonant cavity device connected through magnetic coupling. The design scheme of the brain nerve stimulator provides a general method for inhibiting epilepsy. The brain nerve stimulator can be extended to target brain deep layers or surface areas and peripheral nervous systems. A stimulation mode can be wirelessly transmitted and controlled. It is proved by electroencephalogram recording of free-moving mice that the wireless nerve stimulator can effectively relieve seizure events of the epileptic mice in vivo.

The present invention provides methods for targeting an agent to the peripheral nervous system of a subject. In these methods, targeting is achieved by conjugating the agent to an antibody that can transport conjugated cargo across the blood-nerve barrier. Conjugates comprising an agent conjugated to an antibody are also provided.

Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention discloses application of a peripheral nervous system Mas related G protein coupled receptor D as a target spot in preparing and screening a medicine for relieving opioid medicine tolerance. The invention also provides a pharmaceutical composition for regulating and controlling the tolerance of the opioid drugs. The pharmaceutical composition contains a Mas related G protein coupled receptor D siRNA sequence as shown in SEQ ID NO. 1 or a Jun siRNA sequence as shown in SEQ ID NO. 2. The invention also provides an in-situ hybridization kit for detecting the expression of the Mas related G protein coupled receptor D gene in the dorsal root ganglion tissue of the peripheral nervous system. According to the invention, a new path for accompanying diagnosis and intervention of opioid drugs is expanded.

The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2 / Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.

The present application includes compounds of Formula I and Formula II, compositions containing these compounds, and uses thereof, particularly for treating central nervous system (CNS) or peripheral nervous system (PNS) diseases, disorders, or conditions, and for promoting or improving wound healing (Formula I / II). I / II.

The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of an extract of Gastrodia elata, citicoline, L-acetylcamitine, at least one vitamin of group B and at least one vitamin of group D. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the central and of the peripheral nervous system.

The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2 / Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particularly in the treatment of disorders of the central nervous system (CNS), such as, for example, epilepsy and neurodegenerative disorders, and of the peripheral nervous system (PNS), such as, for example, chronic and neuropathic pain.

Device for the preventive blocking of neurotropic viruses in the peripheral nervous system, comprising a biochemical injection system for the localized release of a neurospecific binding molecule, a detection unit for the identification of viral particles in neuromuscular tissue, and a receptor bait structure for binding viral glycoproteins with affinity for neuronal receptors, characterized in that the device prevents retrograde axonal viral transmission without permanently impairing the conductivity of the nerve tissue.

The present invention relates to novel compounds of Formula (I), wherein Z, P, Q, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-(γ)-aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of central and peripheral nervous system disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of disorders and diseases in which GABAB-R is involved.

The disclosure relates to the field of chronic pain and the treatment thereof. The disclosure involves antisense oligonucleotides and the use thereof in pre-mRNA and mRNA modulation, in one aspect related to RNA editing using endogenous ADAR enzymes, in targeting an adenosine in a (pre-) mRNA for human Nav1.7, preferably to change from a lysine residue to an arginine residue in the protein at position 1406 (K1406R), thereby impairing the ability of the Nav1.7 protein to act as a sodium ion channel. In another aspect the disclosure relates to exon skipping wherein antisense oligonucleotides are used to induce skipping of exon 23 in the generation of human SCN9A mRNA thereby generating a shortened Nav1.7 protein with an impaired ability to act as a sodium ion channel. The disclosure relates to methods and means to alter the Nav1.7 protein in cells of the peripheral nervous system, preferably large nociceptor cells (type Aα / Aβ), to provide a treatment of chronic pain.

Methods for diagnosing a peripheral nervous system (PNS) neuropathy comprising administering to a subject in need of treatment thereof, at least one of a translocator protein (TSPO)-targeting compound or a PSMA-targeting compound and taking an image, are disclosed.

The present disclosure features a chemical compound (e.g., a compound or its pharma- ceutically acceptable salt, or its N-oxide) that is a positive allosteric modulator of one or more GABA-A receptors, e.g., a peripherally restricted positive allosteric modulator of one or more GABA-A receptors that selectively targets the peripheral nervous system and organs of the body and does not substantially cross the blood-brain barrier. The compound is useful, for example, for treating systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders mediated by GABA-A neuronal activity). The present disclosure also features pharmaceutical compositions containing the chemical compounds described herein, and methods of use thereof for treating systemic diseases of the body.

The invention provides an application of a nitrogen-containing heterocyclic ring compound in preparation of a medicine for treating peripheral neuropathy. The nitrogen-containing heterocyclic ring compound is SB203580. The peripheral neuropathy refers to diseases or injuries involving a peripheral nervous system, and comprises peripheral nerve trauma, adverse drug reaction and axonal dysfunction caused by one or more pathogenic factors of chemical reagents and diabetes mellitus. Researches show that recovery of a sciatic nerve function index (SFI) after peripheral nerve physical injury (sciatic nerve truncation) of a mouse is remarkably improved, the recovery degree of the signal transduction rate of the injured sciatic nerve is improved, myelin sheath regeneration of the injured sciatic nerve is promoted, and the proportion of abductive myelin sheaths in newly formed myelin sheaths is reduced. The invention provides a new potential medicine for treating the peripheral nerve injury. The structure of the SB203580 is shown in the specification.

The invention concerns nanovesicles of nanostructured myelin and uses thereof in the treatment of demyelinating and neurodegenerative diseases of the central (CNS) and peripheral (PNS) nervous system. Under another aspect, processes for the preparation of myelin nanovesicles having particular characteristics that make them suitable for recovery of the myelin sheath, where it is compromised, as a drug delivery system for CNS or PNS, and for immunotolerance, are described.

The invention discloses an electrode slice implantation device for mouse vagus nerve electrical stimulation. The electrode slice implantation device comprises an implantable pulse generator, a spiral electrode array, a connection guiding system and an in-vitro program control device. A battery and a microcomputer chip are arranged in the implantable pulse generator; the spiral electrode array is a multi-contact electrode made of a platinum-iridium alloy wrapped by a flexible silica gel carrier; in the connecting wire system, a near-end electrode is positioned on the vagus nerve, and a far-end electrode is anchored on the chest wall fascia to prevent displacement; compared with the prior art, the device has the advantages that the device has low-cost and high-efficiency functional stimulation for nerve tracts with the diameter smaller than 1.0 mm, and low-frequency current for a peripheral nervous system can be recorded and modulated.

The present invention relates to an electrode module (100) for stimulation of the central and / or peripheral nervous system and / or recording of one or more signals of the central and / or peripheral nervous system. The electrode module comprises an electrode module per-product (120), in particular a stimulator lead, including a substrate (110) and at least one electrode (102) disposed on a surface of the substrate (110), a porous graphene layer (114) coated on the at least one electrode (102), and an adhesion layer (105) disposed between the at least one electrode (102) and the porous graphene layer (114) for enhancing the binding of the porous graphene layer (114) to the at least one electrode (102). Further, the present invention provides for a method (200) for preparing the electrode module.

The present invention relates to an animal model of cerebellar atrophy, and more specifically, to an animal model in which cerebellar atrophy occurs due to a deletion of the RaRF gene in cerebellar granule cells, neural stem cells of the central nervous system, or neural stem cells of the peripheral nervous system. The animal model of cerebellar atrophy can be used for research on the pathogenesis, diagnosis, prevention, or treatment of cerebellar atrophy, and can be used for screening therapeutic agents for cerebellar atrophy.

(I) The present invention relates to novel compounds of Formula (I), wherein Z1, Z2, Z3, Z4, A, B, m, n, R1 and R2 are defined as in Formula (I); which are gamma-()- aminobutyric acid type B receptor ("GABAB-R") positive allosteric modulators which are useful for the treatment or prevention of central and peripheral nervous system disorders associated with GABA dysfunction and diseases in which the GABAB receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of disorders and diseases in which GABAB-R is involved.

A balance prosthesis device for an individual including a sensor module configured to obtain a sensor signal indicative of a balance or equilibrium state of the individual, a processing module configured to determine at least one neurostimulation signal based at least in part on the obtained sensor signal, and a transmitter module configured to transmit the determined neurostimulation signal to a neurostimulation device of the individual. The neurostimulation signal is configured to elicit an artificial sensation in a specific sensory cortex area of the individual via directly stimulating afferent sensory axons of the central or peripheral nervous system of the individual targeting sensory neurons of the sensory cortex area not directly associated with vestibulocortical pathways of the individual. The elicited artificial sensation provides a balance indication to the individual in order to support, mimic, substitute or enhance the natural sense of balance of the individual.

The present application includes compounds of Formula I and II, compositions comprising these compounds and uses thereof, in particular for treatment of central nervous system (CNS) or peripheral nervous system (PNS) diseases, disorders or conditions, and for promoting or improving wound healing. (Formula I / II)

The present disclosure provides methods for treating neurological disorders (e.g., trauma of peripheral nervous system (PNS) or central nervous system (CNS)) using anti- Nogo-A antibodies or antigen-binding fragments thereof.

The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of an extract of Gastrodia elata, citicoline, L-acetylcarnitine and at least one vitamin of group B. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the central and of the peripheral nervous system.

The present invention provides an adeno-associated virus (AAV) vector and use thereof. The AAV vector comprises a nucleic acid fragment encoding a secreted tat-degradation peptide. The AAV vector designed in the present invention can be continuously expressed in the peripheral nervous system, where the expressed degradation peptides can cross the blood-brain barrier and cell membranes to exert long-term therapeutic effects in central nervous system (CNS) diseases. Additionally, the vector can also be continuously expressed in the CNS, where the degradation peptides cross the cell membrane to mediate its effects in both AAV-infected and non-infected cells. Therefore, the present invention offers an AAV vector that enables widespread and long-acting delivery of a therapeutic degradation peptide.

The invention discloses application of an ETS family transcription factor ELK1 in preparation of a medicine for treating peripheral neuropathy. The invention proposes and verifies that the ETS family transcription factor ELK1 can effectively regulate and control the physiological activity of Schwann cells in a peripheral nervous system for the first time, especially the directed migration function and migration speed; a new direction is provided for research and development of drugs for treating Schwann cell-derived diseases and diseases caused by nerve injury.

A method of providing electrical stimulation therapy to a patient according to one embodiment includes generating an un-tuned electrical noise signal by at least one noise generator, partitioning the un-tuned electrical noise signal into a plurality of discrete frequency bands having corresponding bandwidths, delivering the un-tuned electrical noise signal through one or more electrodes to the patient to target the patient's central or peripheral nervous system, adjusting, for each of a plurality of selected frequency bands, an amplitude of the voltage or current of the un-tuned electrical noise signal within a corresponding frequency band to generate an adjusted electrical stimulation signal based on feedback received from the patient, wherein the adjusted electrical stimulation signal includes a plurality of local maxima and a plurality of local minima, and delivering the adjusted electrical stimulation signal through the electrodes to provide electrical stimulation therapy to the patient.

Disclosed herein is a system and method for implementing a personalized ultrasound neuromodulation system and methods with neural sensing of personalized electrophysiological data, guiding ultrasound targeting and dosage using such personalized data. Specific ultrasound transducer solutions are provided for various neural targets that enable the low-intensity focused ultrasound to modulate the central nervous system and peripheral nervous systems to treat a variety of neurological and mental disorders. A portable ultrasound console device, a wearable guiding apparatus and a compact solution for effectively and safely enabling point-of-care neuromodulation, e.g., home healthcare, are provided. Further methods for ultrasound waveform customization are also described to improve effectiveness of ultrasound neuromodulation.

The present invention relates to a composition comprising an extract of a fungus belonging to the family Hymenochaetaceae, for use in the treatment or prevention of a pathological condition of the central and / or peripheral nervous system. Preferably, the fungus belonging to the family Hymenochaetaceae is Inonotus obliquus (Chaga). Furthermore, the invention relates to a food supplement comprising the Chaga mushroom.